Cargando…

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

BACKGROUND: Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC. CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Chanhee, Bellone, Stefania, Zammataro, Luca, Schwartz, Peter E., Santin, Alessandro D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014583/ https://www.ncbi.nlm.nih.gov/pubmed/29946554 http://dx.doi.org/10.1016/j.gore.2018.05.011

Ejemplares similares

Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma
por: Bikhezar, Fatima, et al.
Publicado: (2019)

LTBK-04. LATE BREAKING ABSTRACT: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study
por: Robison, Nathan, et al.
Publicado: (2022)

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
por: Bendell, Johanna C, et al.
Publicado: (2017)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma
por: van Herpen, Carla M.L., et al.
Publicado: (2019)

A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor
por: Rosenbaum, Evan, et al.
Publicado: (2019)

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
por: Grisham, Rachel N., et al.
Publicado: (2023)

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
por: Monk, Bradley J., et al.
Publicado: (2020)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
por: Han, Chanhee, et al.
Publicado: (2018)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

MEK-Inhibitor-assoziierte Retinopathie unter Binimetinib-Therapie bei kutanem malignem Melanom
por: Groselli, S., et al.
Publicado: (2020)

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
por: Llaurado Fernandez, Marta, et al.
Publicado: (2022)

A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma
por: Bauer, Sebastian, et al.
Publicado: (2023)

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression
por: Woodfield, Sarah E., et al.
Publicado: (2016)

The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma
por: Chesnokov, Mikhail S., et al.
Publicado: (2021)

A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib
por: Takekuma, Munetaka, et al.
Publicado: (2016)

Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers
por: Feng, Zheng, et al.
Publicado: (2017)

Improved survival of patients with hypermutation in uterine serous carcinoma
por: Santin, Alessandro D., et al.
Publicado: (2015)

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
por: Fernandez, Marta Llaurado, et al.
Publicado: (2019)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum
por: Gershenson, David M., et al.
Publicado: (2020)

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
por: Santin, A D, et al.
Publicado: (2004)

Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment
por: Vetter, Marcus, et al.
Publicado: (2022)

Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
por: Vanguri, Rami, et al.
Publicado: (2022)

Binimetinib plus encorafenib for metastatic melanoma
Publicado: (2019)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
por: Smith, Philip, et al.
Publicado: (2023)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
por: Marchocki, Zibi, et al.
Publicado: (2022)

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020)

Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance
por: Ricciardelli, Carmela, et al.
Publicado: (2017)

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
por: Davis, Jessica, et al.
Publicado: (2022)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
por: Lee, Yong Jae, et al.
Publicado: (2022)

Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
por: Crispin-Ortuzar, Mireia, et al.
Publicado: (2023)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sp2c0l1obvpb10didu6om246bq